Table 1.
Effect of patient plasma on in-vitro thrombin generation
| aCL | Anti-β2GPI | |||||||
|---|---|---|---|---|---|---|---|---|
| Group* | Thrombosis | LA | IgG | IgM | IgG | IgM | Anti-PT IgG | % unaltered thrombin generation, mean ± s.d. |
| A (n = 8) | – | n.d. | 0/8 | 0/8 | n.d. | n.d. | n.d. | 135 ± 37 |
| B (n = 12) | – | 10/12 | 7/12 | 4/12 | 2/10 | 2/8 | 3/12 | 63 ± 36 |
| C (n = 13) | + | 13/13 | 8/13 | 4/12 | 7/13 | 6/11 | 6/12 | 26 ± 16 |
| D (n = 5) | – | 5/5 | 0/5 | 0/5 | 0/5 | 1/3 | 3/5 | 49 ± 14 |
| E (n = 8) | – | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | 79 ± 15 |
Group A: healthy subjects. Group B: antiphospholipid (aPL) antibodies without thrombosis. Group C: aPL antibodies with thrombosis. Group D: aPL antibodies in patients secondary to infection or medication. Group E: Patients on warfarin Results of anova: P < 0·001 for A versus B, A versus C, A versus E and C versus D. P < 0·01 for A versus D, B versus C and D versus E. P < 0·05 for C versus E. P > 0·05 for B versus D and B versus E. n.d. test not done.